FERTIOVONCT06724471
Preservation of Women's Fertility: Evaluation of Innovative Methods for Ovarian Tissue Cryopreservation
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Minor Trial status: Recruiting to Active, Not Recruiting
- Secondary endpoints: 8 to 11
- Site details revised
- Study description expanded, about 3 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Pericystic ovarian cortex will be cut into 1mm3 fragments and either directly analyzed on the day of collection (D0) or after organotypic culture (D7 and D14).
Pericystic ovarian cortex will be cut into 1mm3 fragments, frozen using a slow programmable freezing device (Nano Digitcool, Cryo Bio System) in thermosoldered cryovials and stored in liquid nitrogen (-196°C). Then, fragments will be thawed before being analyzed on the day of thawing (D'0) and after 7 and 14 days (D7 and D14) of organotypic culture.
Pericystic ovarian cortex will be cut into 1mm3 fragments, frozen using a slow programmable freezing device (Nano Digitcool, Cryo Bio System) in screwed cryovials and stored in liquid nitrogen (-196°C). Then fragments will be thawed before being analyzed on the day of thawing (D'0) and after 7 and 14 days (D7 and D14) of organotypic culture.
Devices: Human ovarian tissue cryopreservation using thermosoldered or screwed cryovials
Sites
1 site in 1 country
- University HospitalClermont-Ferrand, France